Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer
Emily Hinchcliff(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), David M. Gershenson(The University of Texas MD Anderson Cancer Center), Aaron Shafer(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Raghu Vikram(The University of Texas MD Anderson Cancer Center), Pamela T. Soliman(The University of Texas MD Anderson Cancer Center), Naomi Adjei(The University of Texas MD Anderson Cancer Center), David Vining(The University of Texas MD Anderson Cancer Center), Anne Knisely(The University of Texas MD Anderson Cancer Center), Cai Xu(Ohio University), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Tharakeswara Bathala(The University of Texas MD Anderson Cancer Center), Charlotte C. Sun(The University of Texas MD Anderson Cancer Center), Nicole D. Fleming(The University of Texas MD Anderson Cancer Center), Anil K. Sood(The University of Texas MD Anderson Cancer Center), Ami Patel(The University of Texas MD Anderson Cancer Center), Larissa A. Meyer, Dhakshina Moorthy Ganeshan(The University of Texas MD Anderson Cancer Center), Ying Yuan(The University of Texas MD Anderson Cancer Center)
Cited by 18
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
|Nature Medicine|2023|508
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
|Journal of the National Comprehensive Cancer Network|2019|332